Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.73 |
| ▸ | GBA1 | P04062 | 6/20 | 0.61 |
| ▸ | GUSB | P08236 | 2/20 | 0.59 |
| ▸ | GBA2 | Q9HCG7 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | UGCG | Q16739 | 3/20 | 0.45 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | SI | P14410 | 2/20 | 0.45 |
| ▸ | AGL | P35573 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL3378979 | 0.94 | GUSB (0.70) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL3378984 | 0.86 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL2435892 | 0.86 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL2435887 | 0.86 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL2435889 | 0.86 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL2437297 | 0.86 | GLB1 (1.00) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL3234285 | 0.82 | GLB1 (0.91) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL18191086 | 0.80 | GUSB (0.88) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL15599061 | 0.80 | GUSB (0.88) | GLB1GBA1GUSBGBA2GAA | |
| SCHEMBL15599058 | 0.78 | GUSB (0.92) | GLB1GBA1GUSBGBA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323651-A2 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | Summit Corporation Plc (GB) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010049678-A2 | TREATMENT OF ENERGY UTILIZATION DISEASES | SUMMIT CORPORATION PLC (GB) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010015815-A2 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2010-02-11 | — | — | WO | disclosed |